Abdominal aortic aneurysms (AAAs) mostly occur in humans over 65 years old ( 1, 2 ). The most dreaded complication of AAA is rupture, and it is the 13th leading cause of death in the United States ( 1 ). At the present time, there is no effi cacious pharmacological therapy, and the surgical treatments carry a high mortality ( 2 ). In the past decades, many studies supported the view that infl ammation played an essential role in the pathogenesis of the disease ( 2-4 ).
analysis. Some aortic tissues were obtained and kept frozen in liquid nitrogen immediately, and then stored at Ϫ 80°C for Western blot and gelatin zymographic analysis. Three micron cross-sections were prepared and subsequently stained with hematoxylin and eosin, and van Gieson, respectively. Immunohistochemical staining was performed according to the manufacture's description (Zsbio, Beijing, China) as described ( 19, 22 ) . The following antibodies were applied: matrix metalloproteinase (MMP)2, MMP9, CD68, and monocyte chemotactic protein-1 (MCP-1) from Santa Cruz Biotechnologies (Santa Cruz, CA). The immunohistochemical staining results were quantifi ed by Image Pro Plus software as described previously ( 19 ) . For quantifying elastin degradation, a standard for the grades of elastin degradation was applied as described previously ( 21 ) . The grades were defi ned briefl y as follows: grade 1, no degradation; grade 2, mild elastin degradation; grade 3, severe elastin degradation; and grade 4, aortic rupture ( 21 ) .
Determination of MMPS activity
The evaluation of MMPS activity was performed as described previously ( 23 ) . Twenty micrograms of protein in tissue homogenates was electrophoresed in SDS-PAGE gels containing 1 mg/ml gelatin. Gels were washed in 2.5% Triton X-100 for 30 min and incubated overnight in zymography developing buffer at 37°C. Gels were stained with Coomassie brilliant blue.
Evaluation of serum and urine EETs and dihydroxyeicosatrienoic acids
Serum and urine samples from all mice were collected. ELISA kits (Detroit R and D, Detroit, MI) were used to determine concentrations of the 11,12-and 14,15-EETs, and their stable metabolites 11,12-and 14,15-dihydroxyeicosatrienoic acids (DHETs) in serum and urine as described previously ( 24 ) .
Measurement of serum lipid profi les
Serum concentrations of total cholesterol, triglyceride, LDL, and HDL were measured with the indicated kits (Biosino, Beijing, China) following the manufacturer's instructions.
Cell culture and treatments
Vascular smooth muscle cells (VSMCs) were harvested from the aortas of wild-type C57BL/6 mice as previously described ( 21, 25 ) . VSMCs and RAW264.7 cells (ATCC, VA), a mouse macrophage cell line, were cultured in 10% FBS (Gibco, Grand Island, NY) containing DMEM (Gibco) under 37°C and 5% CO 2 conditions. After confl uence, VSMCs were incubated with 10 mol/l Ang II (Sigma-Aldrich) for 12 h. If needed, 100 nmol/l 8,9-, 11,12-, or 14,15-EET (Sigma-Aldrich), 10 mol/l compound 26 (C26) (specifi c CYP2J2 inhibitor synthesized in our laboratory), 1 mol/l GW9662 (Sigma-Aldrich), and 10 mol/l BAY 11-7082 (Sigma-Aldrich) were added 1 h before Ang II treatment. For rAAV-CYP2J2 or rAAV-GFP transfection, VSMCs were plated in 6-well plates , and after 60% confl uence, viral solutions of rAAV-CYP2J2 or rAAV-GFP were added respectively ( 26 ) , and incubated for 7 days.
Luciferase assays
The PPAR and nuclear factor B (NF-B) reporter kits were purchased from SABiosciences (Valencia, CA). For PPAR activation assay, HEK293 cells were transfected in 24-well plates with pcDNA-PPAR ␥ , PPAR-reporter, or negative control by Lipofectamine 2000 reagents (Invitrogen, Carlsbad, CA) for 24 h. Cells were then treated with or without 100 nmol/l 11,12-EET, DMSO, or 1 mol/l GW9662. For NF-B activation assay, HEK293 cells were transfected with NF-B reporter or negative control for 24 h, rosiglitazone could reduce the progression and rupture of AAA in mice. Regarding the essential role of infl ammation during AAA development ( 3, 4 ), we therefore hypothesized that increased EETs resulting from CYP2J2 overexpression in vivo may prevent the development of AAA in mice potentially via its anti-infl ammatory effects through PPAR ␥ activation.
In this study, we examined the benefi cial effects of recombinant adeno-associated virus (rAAV)-mediated CYP2J2 overexpression on Ang II-induced AAA in apoEdefi cient (ApoE Ϫ / Ϫ ) mice. Our data strongly suggest that rAAV-mediated CYP2J2 overexpression is protective against AAA development, which is potentially mediated by PPAR ␥ activation to reduce aortic infl ammation.
MATERIALS AND METHODS

Construction and preparation of rAAV vectors
The rAAV vectors (type 2) containing CYP2J2 or green fl uorescent protein (GFP) were produced by triple plasmid cotransfection in HEK293 cells as previously described (17) (18) (19) . The vectors were purifi ed, titered, and stored at Ϫ 80°C before use.
Animals
ApoE
Ϫ / Ϫ mice (C57BL/6 background, n = 32) were housed at the animal care facility of Tongji Medical College under specifi c pathogen-free conditions, and were fed with normal diet. 
AAA model and gene delivery protocols
AAAs were induced in ApoE Ϫ / Ϫ mice by a 28 day continuous Ang II (1,000 ng/kg/min) (Sigma-Aldrich, St. Louis, MO) infusion by subcutaneous osmotic pump implantation as described previously ( 16, 20 ) . Thirty-two 8-week-old ApoE Ϫ / Ϫ mice were randomly assigned into 4 groups: control group (n = 8), receiving saline; Ang II group (n = 8), receiving Ang II (1000 ng/ kg/min); Ang II + rAAV-GFP group (n = 8), receiving Ang II (1,000 ng/kg/min) infusion supplemented with rAAV-GFP injection; and Ang II + rAAV-CYP2J2 group, receiving Ang II (1,000 ng/kg/min) infusion supplemented with rAAV-CYP2J2 injection. For animals in the Ang II + rAAV-GFP and Ang II + rAAV-CYP2J2 groups, corresponding rAAV-GFP and rAAV-CYP2J2 (1 × 10 11 pfu) respectively, were injected via tail veins 4 weeks before Ang II infusion.
Analysis and quantifi cation of AAA
Animals were sacrifi ced at the end of the interventions. For AAA quantifi cation, the maximum width of the abdominal aorta was measured in each mouse by Image Pro Plus software (Media Cybernetics, Bethesda, MD). AAA in mice was defi ned as a 50% or greater increase in the external width of the suprarenal aorta compared with aortas from the controls ( 21 ) .
Macrophage migration determination
Macrophage chemotaxis assay was performed as described previously ( 25 ) . Macrophages (2 × 10 5 ; RAW264.7, a monocyte/ macrophage cell line) were placed in the upper chamber of Costar 24-well transwell plates with 5 m pore fi lters (Corning, Inc., Corning, NY), while the lower chamber was plated with confl uent VSMCs . Ang II (10 mol/l) was added to stimulate macro phage migration. If needed, 100 nmol/l 11,12-EET, 10 mol/l C26, 1 mol/l GW9662, and 10 g/ml anti-MCP-1 antibody (Novus Biologicals, Littleton, CO) or mouse IgG (Novus Biologicals) were added before Ang II incubation. After incubating for 6 h at 37°C, migrated cells on the bottom of the fi lters were stained with DAPI (Sigma-Aldrich) and counted.
Statistical analysis
All data are presented as mean ± SD. After confi rming the normal distribution using the Kolmogorov-Smirnov test, statistical differences were evaluated by ANOVA followed by Bonferroni's multiple comparison test ( 28 ) . P < 0.05 was accepted as statistically signifi cant. and then dosed with 10 mol/l Ang II, 100 nmol/l 11,12-EET, or 1 mol/l GW9662 accordingly. Luciferase activity was determined 6 h after incubation using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) as described previously ( 27 ) .
ELISA analysis of infl ammatory cytokines
The levels of interleukin (IL)-1 ␤ , IL-6, and MCP-1 in mouse serum and in VSMC cultured media were assayed using ELISA kits from R&D Systems (Minneapolis, MN) following the manufacturer's instructions.
Western blot analysis
Tissue samples and cells were harvested and homogenized, and Western blots were performed using the antibodies against MMP2, MMP9, MCP-1, PPAR ␥ , NF-B p65, CYP2J2, GFP, ␤ -actin, lamin B1 (Santa Cruz Biotechnologies), and inhibitor of nuclear factor B ␣ (I B ␣ ) (Cell Signaling Technology, Danvers, MA) respectively . ␤ -actin and lamin B1 were used as internal references for total protein or cytosolic protein determination and nuclear protein determination, respectively. Bands were quantifi ed by densitometry using Quantity One software (Bio-Rad, Hercules, CA). CYP2J2 overexpression suppressed Ang II-induced AAA formation in ApoE ؊ / ؊ mice
We next assessed the effects of CYP2J2 overexpression on Ang II-induced AAA progression. After 4 weeks, Ang II infusion signifi cantly increased the incidence of AAA formation (75%, 6 of 8) and maximal aortic diameters in ApoE Ϫ / Ϫ mice ( Fig. 2 ) . However, rAAV-CYP2J2 treatment markedly lowered the incidence of AAA (25%, 2 of 8) and decreased the maximal aortic diameters ( Fig. 2 ) . MMPs, especially MMP2 and MMP9, are responsible for aortic elastin and collagen degradation, and thus play a key role in the initiation and development of AAA ( 21, 29 ) . Ang II infusion led to a marked increase in MMP2 and MMP9 expression ( Fig. 3A, B and supplementary Fig. I) , as well as their activity in abdominal aortas assayed by gelatin zymography (supplementary Fig. II) , while rAAV-CYP2J2 delivery greatly prevented these effects in abdominal aortic tissue, in contrast. Moreover, CYP2J2 overexpression also markedly inhibited aortic elastin degradation induced by Ang II ( Fig. 3C, D ) . Taken together, these results indicated that CYP2J2 overexpression protected ApoE Ϫ / Ϫ mice against Ang II-induced AAA development.
CYP2J2 overexpression reduced aortic infl ammation and restored aortic PPAR ␥ expression induced by Ang II infusion
Infl ammation plays a central role throughout the progression of AAA ( 3, 4 ) . We found that Ang II infusion substantially increased aortic macrophage infi ltration and MCP-1 expression as evaluated by both immunohistochemical staining and Western blot ( Fig. 4A-D ) . Moreover, serum concentrations of infl ammatory cytokines were also elevated in Ang II-infused mice, while CYP2J2 overexpression markedly suppressed these effects ( Fig. 4E ) . Furthermore, Ang II infusion reduced the aortic expression of PPAR ␥ , while CYP2J2 overexpression signifi cantly attenuated this effect ( Fig. 4F ) . These results suggest that CYP2J2 overexpression is associated with reduced aortic infl ammation, which might possibly be mediated by PPAR ␥ activation.
CYP2J2 overexpression and EETs reduced Ang IIinduced infl ammatory response in VSMCs
VSMCs are the major cellular component in the aorta ( 21 ) . We examined the effects of CYP2J2 treatment on infl ammatory cytokine expression in VSMCs. rAAV-CYP2J2 transfection led to a substantial expression of CYP2J2 in VSMCs (supplementary Fig. III) . Moreover, ELISA analysis showed that CYP2J2 overexpression markedly suppressed the expression of infl ammatory cytokines including IL-6 and MCP-1 induced by Ang II (supplementary Fig. IV) . These effects could be markedly suppressed by C26, a selective CYP2J2 epoxygenase inhibitor (supplementary Fig. V) ( 30 ) .
We next assayed the effects of CYP2J2 metabolites EETs on infl ammatory cytokine expression in VSMCs. As depicted in supplementary Fig. VI, 8,9 -, 11,12-, and 14,15-EETs all markedly reduced IL-6 and MCP-1 expression induced by Ang II in VSMCs, and 11,12-EET exhibited the
RESULTS
Delivery of rAAV-CYP2J2-induced overexpression of aortic CYP2J2 and increased circulating EETs levels in ApoE
؊ / ؊ mice signifi cantly Eight weeks after rAAV-CYP2J2 injection, CYP2J2 expression in the abdominal aortic tissue was abundant as evaluated by Western blot ( Fig. 1A ) . CYP2J2 metabolizes arachidonic acids to form EETs, and EETs can be quickly hydrolyzed to their corresponding DHETs with much lower biological activity. We therefore determined the levels of 11,12-and 14,15-EETs, and their corresponding 11,12-and 14,15-DHETs in serum and urine, respectively. As depicted in Fig. 1B -E , rAAV-CYP2J2 injection caused a signifi cant elevation in both serum and urine levels of 11,12-and 14,15-EETs, as well as their corresponding 11,12-and 14,15-DHETs. Interestingly, we also found that the 11,12-and 14,15-EET levels in Ang II-infused mice were lower than the controls ( Fig. 1B-E ) . These results suggest that the overexpressed CYP2J2 induces production of EETs in vivo.
The effects of rAAV-CYP2J2 delivery on circulating lipid profi les in Ang II-infused ApoE
؊ / ؊ mice ApoE Ϫ / Ϫ mice develop hypercholesterolemia spontaneously. As shown in Table 1 , there were no signifi cant differences in lipid profi les between Ang II-infused mice and the controls. Treatment with rAAV-CYP2J2 lowered the total cholesterol level . However, CYP2J2 overexpression had no signifi cant effects on triglyceride, LDL, and HDL levels among groups, although CYP2J2 had a LDL-lowering trend. in VSMCs. Results showed that 11,12-EET preincubation reduced the expression of IL-6 and MCP-1 induced by Ang II in VSMCs, and GW9662 signifi cantly inhibited these effects of 11,12-EET ( Fig. 5D ). The pro-infl ammatory role of NF-B in VSMCs was further supported by the effects of the NF-B inhibitor BAY 11-7082, which suppressed the Ang II-induced expression of IL-6 and MCP-1 (supplementary Fig. IX ).
CYP2J2 overexpression and 11,12-EET inhibited macrophage migration via PPAR ␥ activation
Infi ltrated macrophages are thought to be the major source of elastase activity in aneurismal tissues ( 25 ) . We applied a macrophage-VSMC coculture system to investigate the effects of CYP2J2 overexpression and 11,12-EET on Ang II-induced macrophage migration. Results showed that Ang II markedly prompted RAW264.7 cells to migrate through a porous membrane, and CYP2J2 overexpression in VSMCs markedly inhibited this chemotactic effect induced by Ang II. CYP2J2 epoxygenase inhibitor C26 signifi cantly blocked this protective effect of CYP2J2 overexpression ( Fig. 6A ) . Because Ang II induced a signifi cant expression of MCP-1 in VSMCs, and CYP2J2 overexpression or its metabolites, EETs, could prevent MCP-1 expression most signifi cant effects . Therefore, we used 11,12-EET as the representative EET in the following studies.
The anti-infl ammatory effects of 11,12-EET are through the PPAR ␥ -mediated NF-B pathway
It has been documented that PPAR ␥ is an effector of EETs ( 15 ), we therefore investigated whether the antiinfl ammatory effects of EETs were mediated by PPAR ␥ activation in VSMCs. Consistent with observations in the in vivo AAA model, Ang II incubation signifi cantly reduced PPAR ␥ expression in VSMCs, and 11,12-EET markedly restrained this effect ( Fig. 5A ). We further found that 11,12-EET markedly induced PPAR ␥ activity in HEK293 cells (supplementary Fig. VII) .
The activation of PPAR ␥ has been shown to inhibit the activation of NF-B. As shown in Fig. 5B , C , Ang II incubation reduced the expression of cytosolic I B ␣ and led to a signifi cant elevation in NF-B p65 nuclear translocation. As expected, pretreatment with 11,12-EET markedly inhibited Ang II-induced NF-B activation, which could be signifi cantly suppressed by addition of GW9662, a selective PPAR ␥ inhibitor ( Fig. 5B, C , supplementary Fig. VIII) .
We assayed the effects of the EET/PPAR ␥ /NF-B pathway in Ang II-induced infl ammatory cytokine expression CYP2J2 and elevated the levels of circulating EETs. rAAV-CYP2J2 delivery reduced the total serum cholesterol level, prevented Ang II-induced aortic MMPs expression and activity, elastin degradation, and retarded AAA formation and development . These effects were associated with upregulation of PPAR ␥ and reduction of aortic infl ammation. Our cellular observations further showed that CYP2J2 overexpression and its metabolic products, EETs, particularly 11,12-EET, suppressed production of Ang II-induced infl ammatory cytokines in VSMCs and prevented Ang II-induced macrophage migration. Moreover, we demonstrated that these protective effects were mediated by the EET/PPAR ␥ /NF-B pathway. CYP2J2 predominantly expresses in the human cardiovascular system ( 5, 31 ). Our previous studies have already reported that using rAAV vectors, CYP2J2 could be successfully overexpressed in rodent tissues and achieve its biological activities ( 11, 13, 19, 32 ) . Indeed, in this study, rAAV-CYP2J2 injection effi ciently overexpressed CYP2J2 in aortic tissue and elevated the serum and urine EET and DHET levels.
The pathophysiology of AAA is complex and involves multiple factors, including age, sex, hypertension, dyslipidemia, elastin and collagen degradation, and infl ammation, etc.
(supplementary Fig. II) , we hypothesized that the released MCP-1 from Ang II-incubated VSMCs is responsible for macrophage migration. As expected, preincubation with a neutralizing antibody to MCP-1 effectively blocked macrophage migration induced by Ang II in the macrophage-VSMC coculture system ( Fig. 6B ) . We further examined the effect of the EET/PPAR ␥ pathway on Ang II-induced macrophage migration in our coculture system. Consistently, 11,12-EET signifi cantly blocked the chemotactic effect of Ang II. However, this effect was markedly suppressed by the addition of PPAR ␥ inhibitor GW9662 ( Fig. 6C ) .
Taken together, these results suggest that the suppressive effect of CYP2J2 overexpression and 11,12-EET on Ang II-induced macrophage migration is mediated by PPAR ␥ activation.
DISCUSSION
The current study investigated the effects of rAAV-mediated CYP2J2 overexpression on Ang II-induced AAA formation in ApoE Ϫ / Ϫ mice. Here, we showed that rAAV-mediated CYP2J2 gene delivery led to an abundant aortic expression of The lipid profi les of rAAV-CYP2J2-treated animals did not change signifi cantly in this study, except for lowered total cholesterol. However, we also do not consider it as the major underlying mechanism of CYP2J2 overexpression to attenuate Ang II-induced AAA progression. Research of statins in the Ang II-induced AAA model led to contradictory results (36) (37) (38) , but it is sure that the protective effects of statins on AAA are independent of lipid lowering ( 36 ) . In addition, HDL and LDL levels are more sensitive predictors of AAA than total cholesterol level ( 39 ), whereas rAAV-CYP2J2 treatment had no signifi cant infl uence on these parameters in the present study.
Aortic infl ammation is a crucial event during AAA development. Recent studies have demonstrated that EETs suppress the infl ammatory response in vitro and in vivo ( 5, 40, 41 ) , and we recently reported that CYP2J2 overexpression reduced infl ammatory responses and protected against heart and renal injury ( 12, 19 ) . Consistent with a previous study of the s-EH inhibitor ( 14 ) , our work demonstrates that CYP2J2 overexpression has a substantial inhibitory effect on vascular infl ammation, which is considered to be the major mechanism of Ang II-induced AAA development ( 4, 20 ) . Our in vitro observations further confi rmed the anti-infl ammatory effects of rAAV-CYP2J2 ( 2, 33 ) . Strategies to elevate circulating EETs have been well documented to be protective against various cardiovascular diseases, including hypertension, heart failure, and atherosclerosis etc. ( 6-10, 12, 34 ) . Although without detailed mechanisms, a recent study of s-EH inhibitor AR9276 showed that elevation of the circulating EETs levels was also protective against Ang II-induced AAA in ApoE Ϫ / Ϫ mice ( 14 ) . We here overexpressed CYP2J2
to increase the circulating EETs levels, and reconfi rmed the protective effects of EETs on Ang II-induced AAA development. The effect of CYP2J2 may involve various mechanisms. Although Ang II clearly elevated blood pressure in this AAA model, and overexpression of CYP2J2 or s-EH inhibitor administration have been reported to lower blood pressure ( 7, 8, 11 ) , it is very unlikely for CYP2J2 overexpression to suppress Ang II-induced AAA. A recent study by Cassis et al. ( 20 ) demonstrated that Ang II infusionpromoted AAA formation was independent of increases in blood pressure . Some other agents, like vitamin E and rosiglitazone, exhibited inhibitory effects on Ang II-induced AAA formation without altering the blood pressure ( 16, 35 ) . Moreover, the s-EH inhibitor AR9276 did not reduce blood pressure in this AAA model ( 14 ) .
other strategies which increase plasma EETs levels, could be novel approaches for the prevention or treatment of AAA development. transfection and its metabolites, EETs, in Ang II-incubated VSMCs.
It is crucial that VSMCs and infi ltrated macrophages synthesize MMPs for AAA development, and the infi ltrated macrophages in the vessel wall present a major source of proteolytic enzymes that weaken the aortic wall ( 42, 43 ) . Indeed, paralleled with reduced aortic macrophage infi ltration, we found CYP2J2 overexpression signifi cantly attenuated vascular MMP expression and activation, as well as elastin degradation in the Ang II-induced AAA model. It has been reported that Ang II induced VSMCs to secrete MCP-1 to stimulate macrophage migration ( 25 ) . Our macrophage-VSMC coculture system showed that CYP2J2 and EETs suppressed Ang II-induced macrophage migration, which further supports our in vivo observation.
EETs activate PPAR ␥ ( 15 ), and PPAR ␥ activation is associated with AAA development ( 16, 44 ) . Studies showed that VSMC PPAR ␥ deletion promotes AAA ( 44 ) , and the administration of the PPAR ␥ agonist, rosiglitazone, prevents AAA progression ( 16 ) . Our cellular experiments suggested an important role of the PPAR ␥ pathway in mediating the anti-infl ammatory effects of CYP2J2 overexpression and EETs. This notion was supported by the addition of the PPAR ␥ antagonist GW9662, which significantly suppressed the protective effects of EETs on NF-B activation and infl ammatory responses in VSMCs, and inhibited macrophage migration induced by Ang II .
In summary, our results demonstrate that rAAV-mediated CYP2J2 overexpression increases EETs levels and can remarkably reduce Ang II-induced AAA development in ApoE Ϫ / Ϫ mice, which is associated with reduced aortic infl ammation and macrophage recruitment. The antiinfl ammatory effects of CYP2J2 overexpression and its metabolites, EETs, are possibly mediated by PPAR ␥ activation. Our data provide evidence that rAAV-CYP2J2 delivery, or Supplemental Material can be found at:
